Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
diabetes drugs
Biotech
UPDATE: Roche muscles in on obesity market with $2.7B Carmot buy
The takeover will give Roche control of Carmot's clinical-phase injectable dual GLP-1/GIP receptor agonists and oral GLP-1 drug candidate.
Nick Paul Taylor
,
Gabrielle Masson
Dec 4, 2023 5:26am
Vertex doubles down on CRISPR Tx and diabetes in new $100M deal
Mar 27, 2023 11:41am
Pfizer accuses former employees of stealing trade secrets
Feb 3, 2022 9:50am
Hanmi's Type 2 diabetes drug curbs cardiovascular, kidney issues
Jun 28, 2021 5:19pm
Lilly's next-gen GLP-1 cuts blood sugar in early-stage diabetes
Jun 26, 2021 4:15pm
Lilly's tirzepatide hits goal in phase 3 diabetes trial
Dec 9, 2020 8:28am